Guidance Warns of Minus 5-13% 2026 Contraction Despite 31% Obesity Growth (NVO Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Novo Nordisk concluded 2025 with robust double-digit sales growth driven by its obesity franchise, but shocked investors with guidance projecting a contraction for 2026. While the rapid uptake of its newly launched oral Wegovy demonstrates undeniable consumer demand, mounting competitive price pressures and generics present significant hurdles for the pharmaceutical giant's near-term profitability.
Obesity Drives 2025 Growth as Wegovy Pill Launches
Novo Nordisk delivered 10% constant exchange rate sales growth in 2025, fueled by a 31% surge in obesity care sales to DKK 31 billion. The injectable Wegovy franchise was the primary growth engine, soaring 134% to DKK 28 billion as the company expanded launches to 35 new countries. The year concluded with the critical U.S. launch of the daily Wegovy pill, which rapidly captured around 50,000 weekly prescriptions by late January, with nearly 45,000 stemming from the self-pay channel.
2026 Guidance Signals Substantial Headwinds
Despite robust volume trends, management issued a stark warning for fiscal 2026, forecasting an adjusted sales decline of 5% to 13% at constant exchange rates. Chief Financial Officer Karsten Munk Knudsen explained that while global GLP-1 volume expansion continues, growth will be countered by lower realized prices. This pricing pressure stems from aggressive investments in market access, mandatory price reductions from the U.S. Most Favored Nations agreements, and the loss of exclusivity for semaglutide in key international markets like Canada.
Pipeline Assets Show Clinical Superiority
On the research and development front, the company highlighted late-stage successes that could defend its market leadership against emerging competition. In the REIMAGINE 2 Phase III trial, CagriSema demonstrated a superior 1.91 percentage point HbA1c reduction and a 14.2% weight loss compared to semaglutide alone. Furthermore, the early-stage oral zenagamtide asset showed dose-dependent HbA1c reductions of up to 1.5 percentage points by week 36, establishing a foundation for a broader Phase III program initiating later this year.
Executive Team Overhaul and Capital Returns
The company announced significant leadership transitions, with U.S. Operations head Dave Moore and Strategy head Ludovic Helfgott departing. Jamey Millar from UnitedHealth and Hong Chow from Merck Healthcare will assume these respective executive roles in February. Meanwhile, Novo Nordisk continued its aggressive capital deployment, announcing a new DKK 15 billion share repurchase program alongside a total 2025 dividend of DKK 11.70 per share, marking its thirtieth consecutive year of dividend increases.